To confirm the therapeutic effect of CXCR2 inhibition, SB225002, a selective CXCR2 inhibitor, was used in bothorthotopic lung cancer model and subcutaneous tumor model (Fig. 5a). This evidence concerns the gene CXCR2 and lung carcinoma.